Crispr Therapeutics AG (CRSP)
NASDAQ · Healthcare
Crispr Therapeutics AG Operating Income 2015–2025
Crispr Therapeutics AG annual/quarterly operating income history and growth rate from 2015 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Crispr Therapeutics AG operating income for the quarter ending March 31, 2026 was -130.2 M, a 12.25% decrease year-over-year.
- Crispr Therapeutics AG operating income for the twelve months ending March 31, 2026 was -640.1 M, a 19.77% increase year-over-year.
- Crispr Therapeutics AG annual operating income for 2025 was -664.6 M, a 42.44% increase from 2024.
- Crispr Therapeutics AG annual operating income for 2024 was -466.6 M, a 109.66% increase from 2023.
- Crispr Therapeutics AG annual operating income for 2023 was -222.5 M, a 66.94% decrease from 2022.
- Crispr Therapeutics AG annual operating income for 2022 was -673.2 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Crispr Therapeutics AG Operating Income — FAQ
Crispr Therapeutics AG (CRSP) operating income over the last 11 years — annual and quarterly figures with year-over-year growth and charts.
What is Crispr Therapeutics AG's operating income?
Crispr Therapeutics AG (CRSP) reported operating income of -$665M for fiscal 2025.
Where can I see CRSP's operating income history?
The chart and table above show Crispr Therapeutics AG's operating income by year and by quarter, including the growth rate.